"10.1371_journal.pone.0079083","plos one","2013-11-04T00:00:00Z","Romana H√∂ftberger; Lidia Sabater; Romain Marignier; Fahmy Aboul-Enein; Rapha√´l Bernard-Valnet; Helmut Rauschka; Anne Ruiz; Yolanda Blanco; Francesc Graus; Josep Dalmau; Albert Saiz","Service of Neurology, Hospital Cl√≠nic, Universitat de Barcelona and Institut d¬¥Investigaci√≥ Biom√®dica August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Institute of Neurology, Medical University of Vienna, Vienna, Austria; Team ONCOFLAM, Lyon Neuroscience Research Center INSERM U 1028/CNRS 5292, Lyon, France; Department of Neurology, SMZ-Ost Donauspital, Vienna, Austria; Instituci√≥ Catalana de Recerca i Estudis Avan√ßats (ICREA), IDIBAPS, Hospital Cl√≠nic, Barcelona, Spain; Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America","Conceived and designed the experiments: RH LS RM FA FG JD AS. Performed the experiments: RH LS RM FA. Analyzed the data: RH AS. Contributed reagents/materials/analysis tools: RH LS RM FA RB HR AR YB FG JD AS. Wrote the manuscript: RH FG JD AS. Statistics: YB.","We have the following interests. Dr. Dalmau has a research grant from Euroimmun and receives royalties from Athena Diagnostics for a patent for the use of Ma2 as autoantibody test, and licensing fees from Euroimmun for a patent for the use of NMDAR as autoantibody test. The patents concerned are: Patent Ma2: US 6,387,639 and Patent NMDAR: US 7972796 B2. There are no further patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","11","Romana H√∂ftberger","RH√",11,TRUE,7,4,2,4,TRUE,TRUE,FALSE,0,NA,FALSE
